Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.37 USD | +14.41% | +24.50% | +11.48% |
Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.48% | 582M | |
-3.18% | 102B | |
+1.36% | 96.29B | |
+2.13% | 22.18B | |
-15.86% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.61% | 16.36B | |
+4.86% | 13.97B | |
+32.17% | 12.17B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- Wedbush Lowers AnaptysBio's PT to $18 From $26, Adjusts Launch Estimates, Addition of Ulcerative Colitis for Rosnilimab; Keeps Neutral Rating